2003
The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients
McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003, 37: 476-482. PMID: 12905130, DOI: 10.1086/376907.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirMethadone metabolismSubstance abuse pharmacotherapyOpiate withdrawal symptomsInjection drug usersConcentration-time curveMethadone areaMethadone dosesHIV diseaseMethadone concentrationsOral clearancePharmacodynamic interactionsWithdrawal symptomsOpiate withdrawalClinical monitoringDrug usersSame dosageRitonavirPotent inducerPatientsMethadoneProtease inhibitorsSignificant reductionR formulationTreatment
1992
Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection.
Schwartz E, Brechbühl A, Kahl P, Miller M, Selwyn P, Friedland G. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1992, 5: 619-26. PMID: 1588496.Peer-Reviewed Original ResearchConceptsIntravenous drug usersControl patientsMethadone patientsPharmacokinetic parametersHigh-pressure liquid chromatographyFormer intravenous drug usersIntravenous drug-using patientsMethadone maintenance therapyDrug-using patientsConcentration-time curveHuman hepatic microsomesZDV levelsZDV therapyZDV treatmentMaintenance therapyMethadone concentrationsMethadone groupHIV infectionPharmacokinetic interactionsSerum levelsConcurrent administrationIVDU patientsUrinary excretionPatientsZidovudine